Abstract Library

#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)

Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: pusceddu s

Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,

Keywords: everolimus,

#482 Well-Differentiated Neuroendocrine Tumors (WDNETs) and Carcinoid Syndrome (CS): A Retrospective Analysis of 110 Patients from Istituto Nazionale Tumori Milano

Introduction: CS is characterized by flushing, diarrhea and carcinoid heart disease (CHD) alone or in association.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pusceddu S, Mazzaferro V, De Braud F, Coppa J, Milione M,

Keywords: carcinoid syndrome,

#480 Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)

Introduction: Recently, gene mutations (SDH complex) involved in the pathogenesis of familial P/P have been discovered. These mutations are often associated with SDHB activity loss and activation of hypoxia signals.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pusceddu S, Milione M, Mazzaferro V, De Braud F, Coppa J,

Keywords: pheochromocytoma, SDHB,

#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?

Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Milione M, Pusceddu S, Mazzaferro V, Buzzoni R, De Braud F,

Keywords: SDHB,